Tower Research Capital (TRC)’s Basel Medical BMGL Stock Holding History

Tower Research Capital (TRC)’s Portfolio BMGL Stock Details BMGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-120	Closed	-$2.57K	–	5751
2025 Q2	$2.57K	Buy	+120	New	+$5.28K	﹤0.01%	4629

Other funds holding BMGL

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WealthCollab Bellevue, Washington $243M AUM 32.93% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return

BIA

Bell Investment Advisors Oakland, California $639M AUM 13.28% 1-Year Est. Return

Tower Research Capital (TRC)'s BMGL Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Basel Medical (BMGL) in Q3 2025, closing a stake of 120 shares — an estimated $2.57K sold.

Tower Research Capital (TRC) first reported a position in BMGL in Q2 2025 and held it in 1 quarter. The position peaked at $2.57K in Q2 2025. 10 funds tracked by Wall St. Rank hold BMGL as of Q3 2025.

Tower Research Capital (TRC) reported no remaining Basel Medical position as of Q3 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 120 Basel Medical shares in Q3 2025, an estimated $2.57K.
Tower Research Capital (TRC) first reported a position in Basel Medical in Q2 2025 and held it in 1 quarter.
Tower Research Capital (TRC)'s Basel Medical position peaked at $2.57K in Q2 2025.
10 funds tracked by Wall St. Rank held Basel Medical as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.